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Improved Cardiac Management with a Disease Management
Program Incorporating Comprehensive Lipid Profiling
John F. McAna, PhD,1 Neil I. Goldfarb, BA,1 Joseph Couto, PharmD,1 Michelle A. Henry, MSN,2
Gary Piefer, MD,2 and George M. Rapier III, MD2
Abstract
The objective of this study was to evaluate the improved effectiveness of a disease management treatment
protocol incorporating comprehensive lipid profiling and targeted lipid care based on lipid profile findings in
patients with ischemic heart disease (IHD) or congestive heart failure (CHF) enrolled in a managed care plan.
This retrospective cohort study, conducted over a 2-year period, compared outcomes between patients with a
standard lipid profile to those evaluated with a comprehensive lipid profile. All adult members of the WellMed
Medical Management, Inc. managed care health plan diagnosed with IHD or CHF, and continuously enrolled
between July 1, 2006 and June 30, 2008, were included in the study. Cases were defined as those who had at least
1 comprehensive lipid test (the VAP [vertical auto profile] ultracentrifuge test) during this period (n = 1767); they
were compared to those who had no lipid testing or traditional standard lipid testing only (controls, n= 289).
Univariate statistics were analyzed to describe the groups, and bivariate t tests or chi-squares examined dif-
ferences between the 2 cohorts. Multivariate regression analyses were performed to control for potential con-
founders. The results show that the case group had lower total costs ($4852.62 vs. $7413.18; P= 0.0255), fewer
inpatient stays (13.1% vs. 18.3% of controls; P = 0.0175) and emergency department visits (11.9% vs. 15.6% of
controls; P= 0.0832). Prescription use and frequency of lipid measurement suggested improved control resulting
from a targeted approach to managing specific dyslipidemias. A treatment protocol incorporating a compre-
hensive lipid profile appears to improve care and reduce utilization and costs in a disease management program
for cardiac patients. (Population Health Management 2012;15:46–51)
Introduction
Cardiovascular disease kills nearly 2400 Americansevery day (2005 mortality data), and 32% of the deaths
occur before age 75.1 One in 5 deaths in 2005 was due to
coronary heart disease.1 The cost of heart disease and stroke in
the United States was estimated to be more than $475 billion
in 2009.2
Heart and vascular diseases can be prevented or mitigated
by modifying risk factors that cause the disease. Aggressive
lowering of cholesterol after a cardiac event produced a 31%
reduction in the rates of fatal and nonfatal heart attack. It
also has been shown to reduce all causes of death by 21%.
The use of cholesterol-lowering drugs can reduce the likeli-
hood of a fatal, heart-related event by 24%–42%.4 Two major
trials (FATS and HATS) demonstrated as much as a 90%
level of risk reduction using combination therapy, including
statins, colestipol, and/or niacin.5,6
Lowering plasma cholesterol, particularly the low-density
lipoprotein (LDL) component, has been the primary target
for clinical intervention. Although elevated LDL is highly
correlated with risk of heart disease, reducing LDL is often
inadequate to reduce risk. The risk factors identified through
the traditional lipid panel identify only 40% of premature
cardiovascular disease7; the Framingham study found that
80% of the study subjects who had a cardiac event had lipid
levels similar to those who were event free.8 Dyslipidemias
leading to cardiovascular disease result from complex gene–
environment interactions and their expression is highly
individual.
The various subclasses of high-density lipoprotein (HDL)
confer varying degrees of protection. HDL2 participates in
1Jefferson School of Population Health, Thomas Jefferson University, Philadelphia, Pennsylvania.
2WellMed Medical Management, Inc., San Antonio, Texas.
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reverse cholesterol transport and may provide a better
measure of protection than total HDL.9 Cholesterol sub-
particles and LDL pattern density and size values reveal,
with greater accuracy, atherosclerotic changes earlier. Results
from a large, population-based, prospective study suggest
that more complete characterization of LDL particles may
improve our ability to predict ischemic heart disease (IHD)
events in men.10 Routine lipid profiles do not detect many of
these dyslipidemias.7
Recognizing the limitations of traditional lipid testing,
new comprehensive lipid profiling tests are being developed
and evaluated. This study evaluated the improved effec-
tiveness of disease management (DM) programs for man-
aged care members with either IHD or congestive heart
failure (CHF). The VAP (Vertical Auto Profile) test devel-
oped by Atherotech, Inc., was used in combination with an
aggressive lipid-lowering protocol in the WellMed DM
program. This test provides not only the standard profile
results, but also LDL density (ie, Pattern A buoyant vs.
Pattern B dense), intermediate-density lipoprotein, HDL
subtypes, very-low-density lipoprotein density, and Lp(a).9
The increased clinical detail provided by this test allows for
more accurate assessment of clinical lipid risk and can result
in more appropriately targeted treatment.
In cooperation with primary care physicians and their
clinics, WellMed physicians used results from the VAP test
with a treatment protocol using combination statin and
Niaspan medication therapy, individually targeted for the
specific dyslipidemias found. Based on LDL and HDL sub-
classes, the VAP test can target individuals with otherwise
normal LDL levels for combination therapy. This could be of
interest to managed care organizations that are looking to
provide better care to their members with cardiovascular
disease, while maintaining a cost-effective approach to
treatment.
Specific aims
A retrospective cohort study was conducted to examine
the impact of a DM program that incorporates a compre-
hensive lipid test on clinical and economic outcomes. We
sought to explore the impact of incorporating the VAP test
into the treatment protocol of a DM program on lipid con-
trol, service utilization for cardiovascular disease episodes,
and direct medical costs. The study also sought to develop a
multivariate model examining the extent to which treatment
guided by periodic comprehensive lipid profiling leads to
improved lipid control.
Methods
Design
The study cohort comprised 1767 members (cases) who
had a diagnosis of cardiovascular disease and who met the
following criteria:
 Enrolled with WellMed continuously for at least the 2-
year period commencing July 1, 2006 (and still living as
of June 30, 2008)
 Enrolled in WellMed cardiovascular DM for at least the
1-year period commencing July 1, 2007
 Had at least 1 VAP test in the 1-year period commenc-
ing July 1, 2007
All cases were patients of medical groups that were both
owned and managed by WellMed. These WellMed-owned
groups contracted to have their lipid testing done with the
VAP test.
The comparison group (controls = 289 members) were
members of 3 large multisite medical groups that were
managed, but not owned, by WellMed. These groups did
their own contracting for lipid testing. The controls met the
same diagnostic, enrollment, and DM inclusion criteria but
did not have a VAP test during the study period.
Seven of 10 of the top diagnosis-related groups (DRGs) for
cases and controls in the first year were the same for cases
and controls. Examination of the Charlson comorbidity index
showed the controls to have a higher risk score based on
comobidities. The mean scores for the cases and controls
were 2.0 and 2.5, respectively. Also, there was no statistically
significant difference in the Risk-Adjusted Factor (RAF)
scores (see following section) between cases and controls.
This study was determined to be exempt from review by
the Thomas Jefferson University (TJU) Institutional Review
Board.
Data collection
WellMed identified members who met the eligibility and
exclusion criteria and provided the research team (TJU) with
data files providing the following information:
 Demographics: age, sex, member months enrolled with
WellMed, and members’ RAF severity scores. The RAF
is a clinical severity score developed and used by the
Centers for Medicare and Medicaid Services and is
based on the principal inpatient diagnostic cost groups
system.10
 Program enrollment history: DM program type (IHD or
CHF) and date of DM program enrollment
 All hospitalizations: date of admission, length of stay,
DRG, and total cost
 All emergency department (ED) utilization: date of visit,
diagnosis (International Classification of Diseases, Ninth
Revision) and cost of visit
 Overall Costs of Care: total claims (inpatient [IP], out-
patient, pharmacy, and labs) paid by year ( July 2006–
June 2007 and July 2007–June 2008)
 VAP test utilization (cases only): dates and findings for
each test
 Other lipid test (non-VAP) results (controls and some
cases)
 Pharmacy utilization: dates of prescriptions, with drug
name, dosage, number of days supplied, amount paid,
and whether prescription was new or a refill.
Statistical analyses
Cases and controls were compared on demographics (age,
sex, RAF severity score, and member months with
WellMed), costs (total, ED, and IP), utilization (occurrence
and numbers of ED visits and IP stays, and IP length of stay)
and LDL level. For costs and utilization, comparisons were
made for the total time of the study (2 years) and for each
year of the study. Comparisons were made on the types and
counts of lipid-related prescription drugs, and compliance
and persistence with prescription utilization (lipid treatment
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drugs). Unpaired t tests were used for comparisons of means,
chi-square tests for counts, and paired t tests were used for
changes in costs and utilization from the first to second study
years.
Linear regression models, controlling for demographics,
enrollment in the IHD and CHF DM programs, first LDL
reading in the study time frame, Charlson comorbidity in-
dex, and RAF were used to examine the impact of status as a
case or control on total claims costs, and total cardiac-related
ER costs and IP costs. A linear regression model was used to
examine the relationship between number of VAP tests re-
ceived during the 2 years of the study and final LDL score.
Logistic regression models for the occurrence of an ED visit
or IP stay were developed using the same independent
variables.
Results
Demographics
Cases were significantly older and averaged more mem-
ber months in DM than controls. These differences, however,
were small (1.8 years and 1.2 months, respectively). Differ-
ences in sex and in the RAF severity score were not signifi-
cant (Table 1).
All cases and controls were in some DM program (both
types). The majority of subjects were in one type of program
(cases: 78%, controls: 68%); however, a higher percentage of
controls were in 2 programs (cases: 22%, controls: 32%).
Looking at specific programs, 90% of the cases and 80% of
the controls were in the IHD program; 32% of cases and 45%
of controls were in the CHF program.
Total claims costs
Total claims costs were higher for controls than cases in
the first year of the study and this gap widened and became
statistically significant in year 2 (Table 2). The regression
model (Table 3) showed that age, claims costs in the first
year, RAF score, and status as case or control were signifi-
cantly associated with claims costs in the second year. This
suggests that status as a case or control has an effect on cost
in year 2 that is distinct from the other variables in the
model. Cases had lower costs.
Hospital utilization and cost
Most cases and controls (87% and 82%, respectively) had
no hospital stays during this time frame. A significantly
higher percentage of controls than cases had a hospital stay
sometime during the 2 years of the study (Table 2). However,
a logistic regression showed no association between status as
a case or control and the occurrence of a hospital stay. Age,
RAF score, enrollment in the IHD program, and enrollment
in the CHF program were significantly associated with the
outcome.
For the total time frame of the study and for each specific
year, the control group had higher percentages of IP stays
and longer stays than cases. Mean IP costs were higher for
controls, but not significantly (Table 2). Using the same re-
gression factors as for total claims costs, similar results were
seen (Table 3).
ED utilization and cost
Cases and controls were compared on whether they made
a visit to the ED in the 2-year period of the study. As with IP
stays, a large majority of both groups (cases: 88%, controls:
84%) had no ED visits during this time frame. Although the
percentages in Table 2 are suggestive of a higher occurrence
of a visit among controls, this difference was not statistically
significant at the P = 0.05 level (P = 0.08). In a logistic re-
gression, controlling for the same variables as in the IP
model, there is no association between status as a case or
control and the occurrence of an ED visit. There were no
significant differences between cases and controls in the
distribution of counts of ED visits. Neither the comparison of
unadjusted costs using the t test (Table 2) nor the linear re-
gression model found a significant association between costs
and status as a case or control (Table 3).
Pharmacy utilization
There was a significant difference between cases and
controls in the distribution of prescription types for control of
lipids. The percentage for each type of drug from the total
number of prescriptions among cases and controls for the 2
years of the study was examined. Some of the major differ-
ences were for Advicor (11.9% of prescriptions for cases vs.
1.7% for controls), Gemfibrozil (2.6% vs. 6.0%), Lovastatin
(19.5% vs. 25.9%), Niaspan (13.0% vs. 5.7%), and Simvastatin
(12.4% vs. 21.2%).
There was a significant difference in the average number
of drug types used by cases and controls for control of lipids
(Table 4). Cases averaged more types used during the 2-year
period of the study. Also, there was a significant difference in
the distribution of the counts of drug types used between
cases and controls. Over 66% of the cases, who were pre-
scribed drugs for lipid control, used more than one type of
drug during the 2 years of the study; less than half (49%) of
the controls did so. Cases were more likely to have used
drugs containing niacin (Niaspan or Advicor) than controls
(36% versus 14%).
Prescription persistence and compliance
with statin use
Persistence was defined as the duration of time from ini-
tiation to discontinuation of therapy. Discontinuation was
Table 1. Demographic Comparisons Between Cases
and Controls
Case Control Test result P value
Sex (% female) 48.5% 49.1% 0.040* 0.8414
Age (mean) 77.7 75.9 3.57** 0.0004
Member months
enrolled in disease
management (mean)
41.6 40.4 5.74** <0.0001
In IHD program 90% 87% 2.26* 0.1330
In CHF program 32% 45% 18.96* <0.0001
RAF disease severity
score
2.11 2.16 - 0.69** 0.4907
Charlson comorbidity
index
2.02 2.48 - 4.03** <0.0001
*Chi-square, **t test. CHF, congestive heart failure; IHD, ischemic
heart disease; RAF, risk adjustment factor.
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marked as a gap of at least 10 days between the end of one
prescription and the filling of the next. Compliance was
measured 3 different ways: (1) total days covered during the
2-year study period, (2) proportion of days covered during
the same time frame, and (3) the medication possession ratio
(MPR). The MPR was similar to the proportion of days
covered; however, the time frame extends from the fill date
of the first prescription to the final day filled for the last
prescription.
A significant difference was noted between cases and
controls in persistence with therapy. Cases, on average, stayed
on therapy longer before the first gap in therapy than controls.
Similarly, cases did slightly, but nonsignificantly, better on all
3 compliance measures than the controls (Table 4).
Relationship between number of VAP tests and final
LDL, HDL2, and HDL3 scores
Table 5 shows the changes in LDL and HDL from first
recorded lipid panel to last panel for both cases and controls.
Both cases and controls showed significant decreases in LDL
levels from first to last test, while improvement (increased
level) in total HDL was seen only among the cases. The re-
sults from the VAP test also allowed us to examine 2 com-
ponents of total HDL: HDL2 and HDL3. Cases showed
significant improvement for both.
Regular monitoring with the VAP test should be related to
better control of lipids. Linear regression models were de-
veloped to examine the association between the number of
VAP tests administered during the 2 years of the study and
the final recorded LDL, HDL2, and HDL3 scores for the
cases. The model controlled for age, sex, RAF score, and
enrollment in CHF or IHD DM; it showed a statistically
significant inverse association between the test count and
LDL level (more tests were associated with lower levels) and
a significant direct association with HDL3 (more tests were
associated with higher levels). The association with HDL2
was not significant (Table 5).
Effectiveness of VAP test at finding dyslipidemias
One of the advantages of the VAP test is its ability to
provide measurement of multiple lipid components not
available in the traditional lipid panels. Taking the 3 main
measures from WellMed’s treatment protocol (LDL level,
LDL density pattern, and HDL2 level), we examined how
often the VAP test detected dyslipidemias that would have
been missed using traditional methods (Fig. 1). There were
5903 VAP tests administered to the cases during the 2 years
of the study. The protocol first looks at LDL level, then LDL
density pattern, and finally HDL2 level. Of the 5903 tests
administered, 66% showed high (> 70mg/dl) levels of LDL
and 34% showed levels at goal. Of the 2015 tests showing
LDL levels < 70mg/dl at goal, 70% showed abnormal pat-
terns (B or A/B small dense LDLc). Finally, of the 612 tests
showing low LDL and pattern A (more buoyant, less dense),
59% showed low HDL2. Of the original 5903 tests, 5640 (95%)
showed some form of dyslipidemia.
Table 2. Utilization and Cost Comparisons
Case Control Test result P value
Utilization
Occurrence of an ED visit (% yes) 11.9% 15.6% 3.00* 0.0832
Mean # ED visits 0.15 0.21 - 1.87** 0.0622
Occurrence of an IP stay (% yes) 13.1% 18.3% 5.65* 0.0175
Mean # IP stays 0.16 0.23 - 2.11** 0.0359
Mean LOS of IP stays 0.41 0.65 - 2.03** 0.0432
Cost
Mean total cost year 1 $4,307.70 $5,141.02 - 1.34** 0.1157
Mean total cost year 2 $4,852.62 $7,413.18 - 2.24** 0.0255
Mean ED costs both years $22.24 $33.15 - 1.92** 0.0561
Mean IP costs both years $732.80 $876.20 - 1.80** 0.0722
*Chi-square, **t test. ED, emergency department; IP, inpatient; LOS, length of stay.
Table 3. Results for Linear Regression Models—Factors Related to Costs
(Total, Inpatient, and Emergency Department) in Year 2 of the Study
Total Claims Costs Inpatient Costs ED Costs
Independent variable Parameter P value Parameter P value Parameter P value
Age - 59.07 0.0695 - 25.22 0.0698 - 3.41 0.0822
Total claims year 1 0.15 <0.0001 0.03 0.0164 0.01 <0.0001
RAF score 2354.59 <0.0001 994.79 <0.0001 97.84 <0.0001
Charlson score - 9.64 0.9518 - 151.14 0.0268 - 20.41 0.0340
Sex 56.06 0.9047 256.78 0.1996 - 81.50 0.0039
IHD enrollment 472.19 0.5882 44.09 0.9058 99.78 0.0579
CHF enrollment - 349.17 0.5573 35.16 0.8900 - 21.20 0.5546
Case vs. Control 2280.04 0.0008 349.59 0.2262 64.84 0.1117
CHF, congestive heart failure; ED, emergency department; IHD, ischemic heart disease; RAF, risk-adjusted factor.
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Discussion
Previous studies have shown that coordinated manage-
ment and aggressive control of lipids after a cardiac event
substantially reduce the occurrence of a second event, and
targeting therapies toward specific subclasses of lipids can
decrease the risk of an event. However, very little has been
done to examine the impact of combining aggressive, tar-
geted management with comprehensive lipid profiling in a
DM setting. WellMed Medical Management, Inc. used this
information to design a lipid treatment plan using a com-
mercial lipid test (VAP) that WellMed felt identified higher
residual lipid risk patients by looking at lipids beyond total
LDL; specifically, small dense LDL class B/AB and HDL2.
Interventions are targeted on the basis of subclass, level, and
pattern of the lipids present. As part of this treatment for
their very high-risk patients, if they had small dense LDLc or
low HDL2, the clinician was encouraged to utilize add-on
Niaspan or to change to fixed-dose Advicor. Initially, this
level of management was provided to DM members from
physician groups in WellMed’s network; it was then offered
to non-WellMed groups for whom WellMed performed DM.
The existence of programs under WellMed management
during the same time period, some of which used the VAP
test/aggressive protocol and some which did not, provided
a natural experiment to evaluate the effectiveness of the
protocol.
Generally, the analyses show a positive impact of the
WellMed approach, using care protocols guided by VAP test
findings, on the outcomes of patients in IHD and CHF DM
programs. Overall, claims costs were lower in the second
year of the study for the cases; this result held after con-
trolling for cost incurred in the first year, disease severity,
and other potential confounders. The occurrence, number,
and length of stay for IP events during the 2 years of the
study also were lower for cases than controls. There were
fewer ED visits for the case group, but the lack of statistical
significance makes it difficult to draw any firm conclusions
about this outcome.
The VAP test can identify multiple dyslipidemias, allow-
ing a provider to prescribe therapy specific to the dyslipi-
demia present. The results, particularly those pertaining to
prescription drug usage, suggest a more targeted and pro-
gressive therapeutic approach being used for the cases
compared to the controls. Cases were more likely to have
been prescribed multiple types of drugs and were more
likely to be prescribed drugs containing niacin than controls.
Along with the established benefit of increasing HDL levels,
recent results from Taylor et al and the ARBITER 6-HALTS
trial demonstrated that the use of extended-release niacin,
when combined with a statin, significantly reduced plaque
buildup in the carotid artery.12 Brown et al also showed that
LDL size and density were correlated with stenosis and that
significant improvements were seen with the use of Sim-
vastatin plus niacin.13 Aggressive use of drugs containing
niacin is an important part of WellMed’s protocol for treating
dyslipidemias. The VAP test enhances their providers’ ability
to identify the appropriate patients for this treatment.
Other results also point to improved management through
the use of the VAP test: among cases, mean LDL, total HDL,
HDL2, and HDL3 levels all improved significantly between
the first and last panels taken during the 2 years of the study.
On average, the final recorded LDL and HDL3 scores for the
cases improved with increasing numbers of VAP tests given
during the 2 years of the study. Using the VAP test allowed
Table 4. Results for Prescription Utilization
Case Control Test result P value
Mean # drug types 2.1 1.8 3.52** 0.0004
Niaspan or Advicor 36.0 14.4 42.17* < 0.0001
Persistence (days) 196.2 166.6 2.01** 0.0447
Compliance:
Days covered 300.9 298.8 0.21** 0.836
% days covered 41.2 40.9 0.21** 0.836
MPR (%) 79.2 76.9 1.67** 0.095
*Chi-square, **t test; MPR, medication possession ratio.
Table 5. Change in Lipid Levels from First Lipid Panel
to Last Taken During the 2-Year Study Period
LDL Total HDL HDL2 HDL3
Cases’ 1st test
(average level)
91.3 46.47 11.96 34.56
Cases’ last test
(average level)
84.5 50.42 12.88 37.54
Avg. difference
(1st - last)
6.64 - 3.95 - 0.92 - 3.02
t test 9 - 16.38 - 8.04 - 18.29
P value <0.001 <0.001 <0.001 <0.001
Controls’ 1st test
(average level)
93.3 50.85
Controls’ last test
(average level)
85.9 49.63
Avg. difference
(1st - last)
6.14 1.21
t test 3.12 1.78
P value 0.002 0.076
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
5,903 VAP tests 
2015 tests (34%) 
LDL <=70 mg/dl 
3,888 tests (66%) 
LDL > 70 mg/dl 
1,403 tests (70%) 
LDL pattern = B or A/B 
612 tests (30%) 
LDL pattern = A 
359 tests (59%) 
HDL2 < 15 mg/dl 
253 tests (41%) 
HDL2 >= 15 mg/dl 
FIG. 1. Dyslipidemias detected by the VAP test following
the WellMed Protocol.
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detection of more cases with dyslipidemia than would have
been identified with the standard lipid panel. Increasing
frequency of monitoring with the VAP test, combined with
adjustments to therapy, led to lower LDL and higher HDL3
levels among these cases. HDL2 also improved but this im-
provement was not strongly associated with the number of
VAP tests given. Figure 1 shows the large number of cases
for whom therapy would not have been adjusted if the
WellMed treatment protocol had not been used.
The results also suggest that significant savings can be
achieved when a comprehensive lipid profile is used in con-
junction with a treatment protocol based on the levels of the
various lipid components. In year 2 of the study, the average
claims costs were approximately $2500 higher for controls
than for cases. The cost of the comprehensive lipid profile is
comparable to standard profiles, takes 1 hour to run, and
eliminates the need for 7 separate Current Procedural Termi-
nology (CPT) procedures. Prospective studies should be per-
formed to more definitively evaluate outcome benefits and
costs using comprehensive lipid testing and management.
There were several limitations to this study. The study
subjects were not randomized into study groups. Status was
determined by the group practice/s to which they belonged.
Although comparable on several factors, other differences
resulting from practice and location could have influenced
the results. The case and control groups may have comprised
patients at different stages/progression of both their disease
and treatment; however, the RAF scores were similar for
both groups. The Charlson comorbidity index showed higher
risk scores for controls; however, regression analyses, which
included and controlled for this variable, did not change the
outcomes presented. Both groups were continuously en-
rolled for the 2 years of the study and showed similar en-
rollment periods prior to the study. The control group was
smaller than the case group, which could have reduced the
possibility of detecting significant differences. Finally, be-
cause of the selection criterion of not having had a VAP test,
there was limited data available on the controls’ lipid levels.
This constrained our ability to compare cases and controls on
the lipid component-specific outcomes of lipid-modifying
therapies.
Despite these limitations, this study suggests that signifi-
cant improvements in cardiac management and clinical and
economic outcomes were achieved by a care management
protocol incorporating periodic comprehensive lipid profil-
ing in a managed care population already enrolled in a
cardiac DM program. Future studies using prospective and
randomized controlled designs are needed to further assess
the impact of comprehensive lipid profiling on care man-
agement, and to better understand which aspects of therapy
appear to be most influenced by lipid findings and lead to
the greatest improvement in health and economic outcomes.
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